Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 20, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements related to the SmithKline Beecham Employee Benefit Trust ("the Trust") and the SmithKline Beecham Annual Investment Plan:
- February 13, 2007: 1,466 Ordinary shares were sold on behalf of plan participants at GBP 14.65 per share. Additionally, 2,154 Ordinary shares were transferred from the Trust to participants.
- February 16, 2007: 2,212 Ordinary shares were transferred from the Trust to participants.
Director Mr. J S Heslop is noted as having an interest in the shares held in the fund, consistent with other non-US employees and former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of shares sold (1,466) and transferred (4,366) from the Trust during the reporting period.
- Confirm the transaction price of GBP 14.65 per share for the February 13 sale.
- Note that Director J S Heslop's interest is derived from his status as a potential beneficiary of the discretionary fund, not a direct personal transaction.
- Understand that this filing contains no financial performance metrics or strategic outlook.